Tessellate Bio Names Dr. Katie Chapman as New CSO
Tessellate Bio has appointed Dr. Katie Chapman as its new Chief Scientific Officer (CSO), effective late September. She succeeds Dr. Jürgen Moll, who will continue to support the company as a consultant while pursuing a news challenge.
Dr. Chapman brings a wealth of experience to her new role. She previously served as Head of Discovery Biology at Tessellate Bio, a position she held before her promotion to CSO. Her career spans senior positions at MSD and Domainex, and she began her pharmaceutical journey at GSK.
Dr. Chapman's academic background includes a PhD from the University of Leeds, UK, focused on the structure and function of GPCRs. She also held an Honorary Research Fellow position at Imperial College London. Since joining Tessellate Bio in 2022, she has significantly advanced the company's pipeline and programmes.
Dr. Katie Chapman's appointment as CSO reflects her impressive track record and the confidence Tessellate Bio has in her leadership. Her expertise will be crucial in driving the company's scientific strategy forward.
